In the fast-evolving landscape of pharmaceutical research, few concepts remain as foundational yet constantly re-evaluated as Lipinski's Rule of 5 (Ro5) . Introduced by Christopher Lipinski in 1997, this rule revolutionized how medicinal chemists screen chemical libraries, providing a rapid heuristic to evaluate whether a chemical compound possesses the physicochemical properties required for...
The clinical research and pharmaceutical sectors in India are undergoing a profound evolution. To streamline drug development, eliminate procedural bottlenecks, and align national standards with global frameworks, the Ministry of Health and Family Welfare (MoHFW) and the Central Drugs Standard Control Organization (CDSCO) introduced the landmark New Drugs and Clinical Trials (NDCT) Amendment...
In modern clinical research, outsourcing operational tasks to Contract Research Organizations (CROs), vendors, and central laboratories is standard practice. However, there is one critical responsibility that a pharmaceutical or biotech sponsor can never outsource: sponsor oversight.
Regulatory authorities worldwide—including the US FDA, EMA, and CDSCO—make it explicitly clear that...
In the rigorous world of pharmaceutical development, proving that a generic or alternative formulation matches a brand-name reference product requires far more than just laboratory similarity. It demands undeniable mathematical and statistical proof. At the heart of this process lies the Pharmacokinetic-Statistical (PK-Stat) Review—the critical link that translates raw plasma...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Greek
